Takahiro Ochiya,
Professor,
Department of Molecular and Cellular Medicine, Tokyo Medical University
Dr. Takahiro Ochiya was a Chief of Division of Molecular and Cellular Medicine at the National Cancer Center Research Institute, Tokyo since 2011 and he is currently appointed as professor of Tokyo Medical University (since 2018). After he got Ph.D. in 1988 in Osaka University and then went to do a post-doc at La Jolla Cancer Research (Burnham Institute for Medical Research), CA, USA. Dr. Ochiya’s lab focuses the development of novel animal models, methods, and strategies to study cancer development and metastasis. Especially, current focuses are siRNA- and microRNA-based therapy against cancer stem cells. Dr. Ochiya is one of top scientist in Exosome research in cancer area and carries President of Japanese Society of Extracellular Vesicles (JSEV) since 2014.
Ultra-Sensitive Liquid Biopsy of Circulating Extracellular Vesicles (EVs) by ExoScreen Method
Thursday, 31 October 2019 at 17:45
Add to Calendar ▼2019-10-31 17:45:002019-10-31 18:45:00Europe/LondonUltra-Sensitive Liquid Biopsy of Circulating Extracellular Vesicles (EVs) by ExoScreen MethodCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
EVs are small membraneous vesicles that differ in their cellular origin, abundance and biogenesis8, and are naturally secreted by almost all cell types to transport bioactive molecules intercellularly. EVs are positive for tetraspanin family proteins, such as CD63, CD81 and CD9, and contain cell surface proteins as well as both mRNA and microRNA. Conventional methods of analyzing EVs generally require large quantities of EVs to be concentrated and processed via time-consuming immunoblotting or enzyme-linked immunosorbent assay (ELISA) assays; these methods are impractical in most clinical settings. In this study, we establish a highly sensitive and rapid analytical technique for profiling surface proteins in EVs from patient blood that can be used to identify biomarkers of colorectal cancer, named ExoScreen. ExoScreen could monitor circulating EVs in serum without the need for purification step. In addition, we show that ExoScreen is superior for the detection of EVs to conventional methods, immunoblotting and ELISA. Furthermore, our results demonstrate that ExoScreen can be a tool for detection of EVs from as little as 5?microliters of cancer patients’ serum to detect circulating cancer-derived EVs.
Add to Calendar ▼2019-10-30 00:00:002019-11-01 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Europe 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com